NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$5.73

-0.17 (-2.88%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.31
▼
$8.93
50-Day Range: $4.46
▼
$7.31
52-Week Range: $1.05
▼
$11.59

Volume: 8.02 million shs
Average Volume: 1.72 million shs
Market Capitalization: $342.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.29

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 79.5% Upside
$10.29 Price Target
Short Interest: Bearish
7.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.86) to ($0.98) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

914th out of 1,072 stocks

Pharmaceutical Preparations Industry

454th out of 534 stocks

3.3

Analyst's Opinion

Consensus Rating
Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.29, Avadel Pharmaceuticals has a forecasted upside of 79.5% from its current price of $5.73.
Amount of Analyst Coverage
Avadel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.20% of the float of Avadel Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Avadel Pharmaceuticals has recently increased by 2.06%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Avadel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Avadel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVDL.

2.0

News and Social Media Coverage

News Sentiment
Avadel Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Avadel Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Avadel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
63.01% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.86) to ($0.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avadel Pharmaceuticals is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avadel Pharmaceuticals is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avadel Pharmaceuticals has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

October 4, 2022 | americanbankingnews.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $10.29 Average Price Target from Analysts

September 22, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

August 25, 2022 | seekingalpha.com

Avadel gains as judge delays hearing on patent dispute with Jazz Pharma

August 10, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Avadel Pharmaceuticals

August 9, 2022 | seekingalpha.com

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call Transcript

August 9, 2022 | msn.com

Avadel Pharmaceuticals: Q2 Earnings Insights

August 5, 2022 | finance.yahoo.com

Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet

August 2, 2022 | nasdaq.com

Would Avadel Pharmaceuticals (NASDAQ:AVDL) Be Better Off With Less Debt?

August 2, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

July 19, 2022 | finance.yahoo.com

Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension

June 29, 2022 | seekingalpha.com

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

June 29, 2022 | finance.yahoo.com

Avadel Pharmaceuticals Provides Corporate Update

June 3, 2022 | finance.yahoo.com

Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum

June 2, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference

June 2, 2022 | finance.yahoo.com

Thomas McHugh Is The Senior VP & CFO of Avadel Pharmaceuticals plc (NASDAQ:AVDL) And They Just Picked Up 233% More Shares

June 1, 2022 | seekingalpha.com

Avadel Pharmaceuticals reports insider transactions from Director, CEO & CFO

May 27, 2022 | seekingalpha.com

Avadel spikes as Oppenheimer says selloff is overdone

May 26, 2022 | markets.businessinsider.com

Mid-Day Market Update: Crude Oil Jumps Over 3%; NRx Pharmaceuticals Shares Tumble

May 26, 2022 | finance.yahoo.com

Avadel's stock falls 21% after disclosing new FDA request for experimental narcolepsy drug

May 19, 2022 | finance.yahoo.com

Avadel to Present Clinical Data for FT218 at SLEEP 2022

May 18, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

May 9, 2022 | seekingalpha.com

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call Transcript

May 9, 2022 | nz.finance.yahoo.com

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 9, 2022 | seekingalpha.com

Avadel Pharmaceuticals GAAP EPS of -$0.45 misses by $0.02

May 9, 2022 | finance.yahoo.com

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings: 8/09/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVDL
CUSIP: N/A
CIK: 1012477
Web: www.avadel.com
Phone: (531) 485-1200
Fax: 353-1526-1077
Employees: 66
Year Founded: 2015

Price Target and Rating

Average Stock Price Forecast: $10.29
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +79.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-77,330,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -175.28%
Return on Assets: -45.09%

Debt

Debt-to-Equity Ratio: 2.11
Current Ratio: 2.72
Quick Ratio: 2.72

Sales & Book Value

Annual Sales: $22.33 million
Price / Sales: 15.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.33 per share
Price / Book: 4.31

Miscellaneous

Outstanding Shares: 59,793,000
Free Float: 57,880,000
Market Cap: $342.61 million
Optionable: Optionable
Beta: 1.43

Social Links

Key Executives

Mr. Gregory J. Divis Jr. (Age 55)
CEO & Director
Comp: $862.59k

Mr. Thomas S. McHugh (Age 57)
Sr. VP & CFO
Comp: $550k

Mr. Richard Kim (Age 53)
Chief Commercial Officer
Comp: $596.3k

Mr. Jerad G. Seurer
Gen. Counsel & Company Sec.

Mr. Gregory J. Davis (Age 57)
VP of Corp. and Bus. Devel.

Mr. Mark W. Elrod
VP of Sales

Ms. Angie Woods
VP of People & Culture

Mr. Christian Kalita Pharm.D
Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs

Mr. Steven G. Sullivan (Age 57)
VP of Sales & Marketing and Head of Commercial Operations

Dr. Jordan S. Dubow M.D. (Age 44)
Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.
What is Avadel Pharmaceuticals' stock price forecast for 2022?: 6 equities research analysts have issued 12 month price targets for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they anticipate the company's stock price to reach $10.29 in the next year. This suggests a possible upside of 79.5% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.
How have AVDL shares performed in 2022?: Avadel Pharmaceuticals' stock was trading at $8.08 at the beginning of the year. Since then, AVDL stock has decreased by 29.1% and is now trading at $5.73.
View the best growth stocks for 2022 here.
When is Avadel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVDL earnings forecast.

How were Avadel Pharmaceuticals' earnings last quarter?: Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its earnings results on Tuesday, August, 9th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.60. During the same quarter in the prior year, the company earned ($0.33) earnings per share.
What other stocks do shareholders of Avadel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).
What is Avadel Pharmaceuticals' stock symbol?: Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
How do I buy shares of Avadel Pharmaceuticals?: Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Avadel Pharmaceuticals' stock price today?: One share of AVDL stock can currently be purchased for approximately $5.73.
How much money does Avadel Pharmaceuticals make?: Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $342.61 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.
How can I contact Avadel Pharmaceuticals?: Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

Avadel Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows